At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.23B, above the global median of $1.14B
- FinancialsAltman Z-Score 13.9: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.23BUSDvs all stocks (USD)
Revenue (TTM)
251.17MUSDvs all stocks (USD)
Profit Margin
-13.36%vs Medical Devices peers
Beta
1.17xvs all stocks
52-Week Change
113.95%vs all stocks
Market Capitalization
2.23BUSDvs all stocks (USD)
Enterprise Value
1.95BUSDvs all stocks (USD)
Forward P/E
52.43xvs Medical Devices peers
Price to Sales (TTM)
8.89xvs Medical Devices peers
Price to Book (MRQ)
7.97xvs Medical Devices peers
Enterprise to Revenue
7.78xvs Medical Devices peers
Gross Margin
72.67%vs Medical Devices peers
Profit Margin
-13.36%vs Medical Devices peers
Operating Margin
-3.09%vs Medical Devices peers
Return on Assets (TTM)
-3.15%vs Medical Devices peers
Return on Equity (TTM)
-18.21%vs Medical Devices peers
Revenue (TTM)
251.17MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.07USDUpdated Oct 26, 2026Quarterly Revenue Growth
23.10%vs Medical Devices peers
Gross Profit (TTM)
187.26MUSDvs all stocks (USD)
EBITDA (TTM)
826.00KUSDvs all stocks (USD)
Net Income (TTM)
-33.55MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.06%vs Medical Devices peers
Operating Cash Flow (TTM)
15.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
18.23MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
225.21MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
57.85MUSDFY2025 · Dec 31, 2025Gross Profit
167.35MUSDFY2025 · Dec 31, 2025Operating Income
-7.85MUSDvs all stocks (USD)
Pre-tax Income
-15.70MUSDFY2025 · Dec 31, 2025Net Income
-15.70MUSDFY2025 · Dec 31, 2025EBIT
-8.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
826.00KUSDFY2025 · Dec 31, 2025Research & Development
32.88MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
142.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.70MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.05MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.05MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
10.26MUSDFY2025 · Dec 31, 2025Free Cash Flow
6.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
39.55MUSDFY2025 · Dec 31, 2025Interest Paid
6.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
30.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
891.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.46MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.75MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.85MUSDFY2025 · Dec 31, 2025Purchase of Investments
-13.72MUSDFY2025 · Dec 31, 2025Sale of Investments
14.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.47MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-32.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-32.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
53.18MSharesUpdated Oct 26, 2026Float Shares
49.06MSharesUpdated Oct 26, 2026Shares Short
4.70MSharesUpdated Oct 26, 2026Short Ratio
3.70daysvs all stocks
Short % of Shares Outstanding
9.14%vs all stocks
% Held by Insiders
1.98%vs all stocks
% Held by Institutions
97.66%vs all stocks
Total Cash (MRQ)
111.41MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.07USDUpdated Oct 26, 2026Total Debt (MRQ)
20.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0783xvs Medical Devices peers
Current Ratio (MRQ)
6.60xvs Medical Devices peers
Book Value per Share (MRQ)
4.78USDUpdated Oct 26, 2026Total Assets
221.69MUSDvs all stocks (USD)
Total Current Assets
120.42MUSDFY2025 · Dec 31, 2025Total Liabilities
92.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
101.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
23.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
35.55MUSDFY2025 · Dec 31, 2025Other Short-term Investments
5.98MUSDFY2025 · Dec 31, 2025Accounts Receivable
26.17MUSDFY2025 · Dec 31, 2025Inventory
42.37MUSDFY2025 · Dec 31, 2025Accounts Payable
2.89MUSDFY2025 · Dec 31, 2025Short-term Debt
2.37MUSDFY2025 · Dec 31, 2025Long-term Debt
65.26MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
141.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
472.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-306.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
128.85MUSDvs all stocks (USD)
52-Week Low
17.14USDUpdated Oct 26, 202652-Week High
52.91USDUpdated Oct 26, 202652-Week Change
113.95%vs all stocks
Beta
1.17xvs all stocks
50-Day MA
43.25USDUpdated Oct 26, 2026200-Day MA
39.25USDUpdated Oct 26, 2026Avg 10-Day Volume
1.31MSharesUpdated Oct 26, 2026Avg 30-Day Volume
1.40MSharesUpdated Oct 26, 2026Diluted EPS (TTM)
-0.6700USDUpdated Oct 26, 2026Other Income / Expense
-152.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.73Profit Margin: -0.13
Financial Health
Altman Z-Score 13.9: safe zoneNotable
Altman Z-Score: 13.90
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.23B, above the global median of $1.14BNotable
Market cap (USD): 2,230,690,924Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Elekta AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk